In the present study, we established a method based on the immune subtype classification of melanoma to identify a tumor immune-relevant (TIR) signature, which could predict the survival outcome as well as the response to anti-CTLA4 treatment in patients with melanoma. The gene discussed is CTLA4; the disease is neoplasm.